A significant increase in IFN-β in COVID-19 would not justify the use of this cytokine as a therapy, unless when targeted directly to the lungs by inhalation, though this will not prevent its rapid entry into the bloodstream. This evidence concerns the gene IFNB1 and COVID-19.